Treace Medical Concepts, Inc. TMCI
Medical/Dental Instruments · IPO 2021 · data as of November 13, 2026
Treace Medical Concepts, Inc. (TMCI) is a healthcare company listed in the US with a market value of about $345M. In the twelve months to September 30, 2026 it had revenue of $203M and net income of -$56M, a net margin of -27.4%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 30% a year, a 5-year average ROIC of -20%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.
About Treace Medical Concepts
Treace Medical Concepts is listed in the US and classified in medical/dental instruments, IPO year 2021. Revenue went from $39M in 2019 to $213M in 2025, growth of about 32.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 14% over three years (dilution for shareholders). It spends 10% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $203M | $213M | $209M | $187M | $142M | $94M | $57M | $39M |
| Net income | -$56M | -$59M | -$56M | -$50M | -$43M | -$21M | -$4M | -$4M |
| Free cash flow | -$19M | -$29M | -$49M | -$46M | -$45M | -$20M | -$6M | -$9M |
| EPS (diluted) | $-0.85 | $-0.93 | $-0.90 | $-0.81 | $-0.77 | $-0.43 | $-0.12 | $-0.13 |
| Net margin | -27.4% | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | -6.4% | -10.8% |
| ROIC | — | -26.9% | -24.1% | -19.5% | -21.3% | -10.7% | 2.1% | -88.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $6.17, 17% above the current price; targets range from $5.00 to $7.00; the consensus rating is “Buy”; expected EPS is $-0.81 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Treace Medical Concepts stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Treace Medical Concepts pay a dividend?
Not currently.
Is Treace Medical Concepts a good stock to buy?
We do not give buy or sell advice. Treace Medical Concepts scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.